| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| ln Vivo |
Ethambutol hydrochloride can be used in animal modeling to produce a high uric acid model.
|
|---|---|
| Animal Protocol |
Mouse Efficacy Study 1:** Mice were infected intravenously. Starting 15 days post-infection, ethambutol was administered orally at a dose of 100 mg/kg, once weekly for 5 weeks. Efficacy was assessed by log CFU reduction. [1]
* **Mouse Efficacy Study 2:** In a separate study, ethambutol was dosed for 12 weeks in combination with other anti-tuberculosis drugs. One group received ETH with isoniazid, while another received ETH on alternate days with rifampin and pyrazinamide. A comparator group received all four drugs (ETH, PZA, INH, RIF) together three times weekly. Efficacy was assessed by CFU counts. [1] |
| References | |
| Additional Infomation |
Ethambutol hydrochloride is a prescription antimicrobial drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of active pulmonary tuberculosis (TB). (Active pulmonary tuberculosis is also known as tuberculosis.) Tuberculosis can be an opportunistic infection (OI) of HIV. Ethambutol hydrochloride is the hydrochloride form of ethambutol, an ethylenediamine derivative with antibacterial activity, particularly effective against mycobacteria. While the exact mechanism of action of ethambutol hydrochloride is not fully understood, it inhibits the transfer of mycolic acid into the bacterial cell wall, thereby hindering bacterial cell growth. The drug may also interfere with RNA synthesis or inhibit other cellular metabolism, thereby preventing cell proliferation and leading to cell death. It is an anti-tuberculosis drug that inhibits the transfer of mycolic acid into the cell wall of Mycobacterium tuberculosis. It may also inhibit spermidine synthesis in mycobacteria. This drug generally has bactericidal activity and can penetrate human cell membranes to exert its lethal effect. (Quoted from Smith and Reynard, Pharmacology Textbook, 1992, p. 863)
|
| Exact Mass |
276.137
|
|---|---|
| CAS # |
1070-11-7
|
| Related CAS # |
Ethambutol;74-55-5
|
| PubChem CID |
14051
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
345.3ºC at 760 mmHg
|
| Melting Point |
198-200°C
|
| Flash Point |
113.7ºC
|
| Vapour Pressure |
3.35E-07mmHg at 25°C
|
| LogP |
2.093
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
16
|
| Complexity |
109
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl.Cl
|
| InChi Key |
AUAHHJJRFHRVPV-BZDVOYDHSA-N
|
| InChi Code |
InChI=1S/C10H24N2O2.2ClH/c1-3-9(7-13)11-5-6-12-10(4-2)8-14;;/h9-14H,3-8H2,1-2H3;2*1H/t9-,10-;;/m0../s1
|
| Chemical Name |
(2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;dihydrochloride
|
| Synonyms |
Ethambutol Hydrochloride Ethambutol HCL 4878
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~360.71 mM)
H2O : ≥ 50 mg/mL (~180.36 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (360.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00002343 | COMPLETED | Drug: Ethambutol hydrochloride Drug: Rifabutin |
HIV Infections Mycobacterium Avium-Intracellulare Infection |
Pharmacia | Phase 4 | |
| NCT01048697 | COMPLETEDWITH RESULTS | Drug: Ethambutol | Obesity Tuberculosis |
Texas Tech University Health Sciences Center | 2010-01 | Phase 4 |
| NCT01994460 | UNKNOWN STATUS | Drug: Linezolid Drug: Ethambutol |
Pulmonary Tuberculosis Without Resistance to Rifampicin | Seoul National University Hospital | 2014-01 | Phase 2 |
| NCT05966688 | COMPLETED | Drug: SPR720 Drug: Azithromycin Drug: Ethambutol |
Healthy Volunteers | Spero Therapeutics | 2023-08-04 | Phase 1 |
| NCT04972903 | UNKNOWN STATUS | Pulmonary Tuberculosis |
Institut National de la Santé Et de la Recherche Médicale, France |
2021-08 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
